COVID-19: Setting the Stage for Improved Outcomes with Targeted TherapiesPremiere Date: Wednesday, December 15, 2021
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 15, 2022
Note: Credit Is No Longer Available
|David Alain Wohl, MD (Moderator)
Professor of Medicine
Institute of Global Health and Infectious Diseases
Site Leader, Global Infectious Diseases Clinical Trials Unit, Chapel Hill Site
The University of North Carolina (UNC) at Chapel Hill School of Medicine
Chapel Hill, NC
|Aima A. Ahonkhai, MD, MPH
Assistant Professor of Medicine
Vanderbilt University Medical Center
Division of Infectious Diseases
Vanderbilt Institute for Global Health
|Onyema Ogbuagu, MBBCh, FACP, FIDSA
Associate Professor of Medicine (AIDS)
Director, Clinical Trials Program, Yale AIDS Program
Section of Infectious Diseases
Yale School of Medicine
New Haven, CT
|Pratish C. Patel, PharmD, BCIDP, AAHIVP
Program Director, Pharmacy
Vanderbilt University Medical Center
The COVID-19 pandemic has challenged the world like no other health-related crisis in modern history, and although vaccines have been shown to stop transmission, far too many people remain unvaccinated; variants may still put unvaccinated and vaccinated individuals at risk for infection. A number of targeted therapies that can stop COVID-19 and be given as simple-to-administer regimens are vital to recovery. There is currently an active and robust field of research surrounding the search for such therapies, but they will only fulfill their potential if used early in the disease course.
This CMEO Live and OnDemand webcast will focus on improving clinicians’ knowledge of the short-term and long-term health consequences of COVID-19 so that they can better identify patients who may be at risk for worse outcomes and will benefit from early treatment.
At the end of this CE activity, participants should be able to:
- Characterize the short-term and long-term disease burden of COVID-19
- Evaluate patients with COVID-19 to make appropriate treatment recommendations to optimize quality of care and patient outcomes.
- Identify best practices to support the utilization of currently approved or authorized agents, and emerging agents for the treatment of COVID-19.
Supported by educational grants from Pfizer Inc. and Merck Sharp & Dohme Corp.
Internists, emergency/urgent care clinicians, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Wohl reports that he receives research support and grants from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He reports that he is on the advisory committee for Gilead Sciences, Inc.; Janssen Pharmaceutical, Inc.; Merck & Co., Inc. and ViiV Healthcare.
Dr. Ahonkhai reports she receives research support from National Institutes of Health (NIH). She is a consultant for the CDC Foundation. She serves on the advisory board for ViiV Healthcare and Gilead Sciences, Inc. (specific to HIV treatment).
Dr. Ogbuagu reports that he receives grants from Gilead Sciences, Inc. He reports that he is on the speakers bureau for Gilead Sciences, Inc. He reports that he is a consultant for ViiV Healthcare.
Dr. Patel has no disclosures to report.
Michael Franks, APRN, AGACNP-BC, FNP-BC
Kathleen Blake, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).